<DOC>
	<DOCNO>NCT02467920</DOCNO>
	<brief_summary>Efficacy Safety Basal Insulin Glargine Combination Exenatide bid v Switching Premix Human Insulin Aspart30 T2DM Inadequate Glycaemic Control Premixed Human Insulin Metformin : Randomized , Open , Parallel trial .</brief_summary>
	<brief_title>Efficacy Safety Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 T2DM</brief_title>
	<detailed_description>This multicentre , open-label , randomized parallel trial compare efficacy safety basal insulin glargine combination Exenatide bid vs. switch premix human insulin aspart30 type 2 diabetic patient inadequate glycaemic control premixed human insulin metformin . Approximately 248 patient enrol study China randomize 1:1 ratio one 2 treatment arm : once-daily insulin glargine + twice-daily exenatide + metformin ; twice-daily aspart 30 + metformin . Study treatment continue 24 week . The primary efficacy measure change HbA1c 24 week . The study consist 3 period : 1-week screening ( period A ) , 12-week run-in period ( period B ) 24-week treatment period ( period C ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Provision inform consent Type 2 diabetic patient receive twicedaily premixed human insulin 30 therapy ≥ 30 U/d metformin maximum tolerate dosage ( ≤ 1500mg/d ) HbA1c &gt; 8.0 % &lt; 11.0 % ( HbA1c &gt; 7.0 % &lt; 10.0 % randomization ) Men woman ( nonpregnant use medically approve birthcontrol method ) age ≥ 18 ≤ 70 year BMI ≥ 23 ≤ 35 kg/m2 Type 1 diabetes specific type diabetes Pregnancy , preparation pregnancy , lactation woman childbearing age incapable effective contraception method Uncooperative subject various reason Abnormal liver function , glutamicpyruvic transaminase ( ALT ) glutamicoxaloacetic transaminase ( AST ) ＞ twice upper limit normal Impairment renal function , serum creatinine : ≥ 133mmol/L female，≥ 135mmol/L male Serious chronic gastrointestinal disease Edema Serious heart disease , cardiac insufficiency ( level III accord NYHA ) , acute coronary syndrome old myocardial infraction Blood pressure : Systolic blood pressure ( SBP ) ≥ 180mmHg and/or diastolic blood pressure ( DBP ) ≥ 110mmHg White blood count ( WBC ) ＜ 4.0×109/L platelet count ( PLT ) ＜ 90×109/L，or definite anemia ( Hb：＜ 120g/L male , ＜ 110g/L female ) , hematological disease Endocrine system disease , hyperthyroidism hypercortisolism Experimental drug allergy frequent hypoglycemia Psychiatric disorder , drug substance abuse Diabetic ketoacidosis hyperosmolar nonketotic coma require insulin therapy Stressful situation surgery , serious trauma Chronic hypoxic disease pulmonary emphysema pulmonary heart disease Combined use drug effect glucose metabolism glucocorticoid Tumor , especially bladder tumor and/or family history bladder tumor and/or longterm hematuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>exenatide</keyword>
	<keyword>glargine</keyword>
	<keyword>aspart 30</keyword>
</DOC>